Korea's LOTTE Biologics secures major commercial manufacturing agreement ahead of Songdo Plant 1 launch
Singapore, Nov. 18 -- South Korea-based LOTTE Biologics has announced a major commercial manufacturing agreement with a global pharmaceutical company, marking a significant milestone in the commercialisation of its Songdo Bio Campus.
Securing commercial manufacturing volume while the facility is still under development underscores customer confidence in LOTTE Biologics' technical expertise, execution capabilities, and long-term supply reliability.
Designed to meet the evolving demands of global biopharmaceutical manufacturing, Songdo Plant 1 features state-of-the-art production infrastructure, advanced automation, and large-scale cold-chain warehousing to support efficient, reliable, and quality-driven operations.
The Songdo Bio Campus...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.